Skip to main content
TipRanks
Go Ultimate75% OFF

Inventiva (6IVA) AI Stock Analysis

2 Followers
DE:6IVA

Inventiva

(Frankfurt:6IVA)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Large late-stage clinical programA large, fully recruited Phase III program provides a substantial clinical test of lanifibranor across relevant MASH stages. The trial’s scale and advanced development status support a potentially meaningful value inflection if efficacy and safety results validate the program.
Negative Factors
Deep and persistent operating lossesSevere losses relative to revenue show that Inventiva has not yet achieved operating leverage and remains dependent on external financing. Continued development spending without commercial product sales could keep profitability distant and increase dilution or funding pressure.

Inventiva (6IVA) vs. iShares MSCI Germany ETF (EWG)

-50%-25%0%25%50%75%100%DE:6IVA+4.22%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 191.29M
Dividend Yield
―
Average Volume (3M)
1,283
Price to Earnings (P/E)
-6.4
Beta (1Y)
1.03
Revenue Growth
-99.64%
EPS Growth
68.67%
Country
Germany
Employees
77
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Inventiva Business Overview & Revenue Model

Company Description

Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepa...

Inventiva Earnings Call Summary

Earnings Call Date:Sep 28, 2026(Q2-2026)|% Change Since:26.28%|Next Earnings Date:Mar 31, 2027
Earnings Call SentimentPositive

The call was strongly focused on progress toward the NATiV3 phase III readout, positive phase II-B efficacy, preparation for potential regulatory and commercial milestones, and a strengthened financial position. Management also addressed known tolerability considerations, including weight gain, edema, and hemoglobin decline, while withholding additional blinded phase III safety and efficacy details. The positive development, financing, and preparation updates significantly outweighed the disclosed challenges and uncertainties.

Positive Updates

NATiV3 Phase III Trial Remains on Track
Inventiva remains on track to report NATiV3 top-line results in the fourth quarter of 2026. The last patient completed the final 72-week visit earlier in September 2026.

Negative Updates

Lanifibranor-Related Weight Gain and Fluid Retention
The phase II-B safety profile included weight gain, edema, and hemoglobin decline associated with partial PPAR gamma activation. The company described these effects as present but attenuated relative to full TZD-class gamma agonists.

Company Guidance

Inventiva remains on track to report NATiV3 top-line data in the fourth quarter of 2026 after the last patient completed their final 72-week visit; the main cohort enrolled 1,009 participants with F2 or F3 fibrosis, and the trial was powered at 90%. Subject to positive phase III results, the company intends to file an NDA with the FDA in the first half of 2027, seek accelerated approval with the FDA and conditional approval with the EMA, and pursue a potential U.S. commercial launch in 2028; current financing provides cash runway until the end of the second quarter of 2027, extending to the start of the first quarter of 2028 assuming full exercise of Tranche 3 warrants and successful completion of Tranche C, while the company expects to initiate a confirmatory outcomes trial in cACLD and has not provided guidance on NATiV3 top-line details, edema over time, or future raises.

Inventiva Risk Analysis

Inventiva disclosed 83 risk factors in its most recent earnings report. Inventiva reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk
1.Through the Royalty Certificates, we transferred to the holders thereof rights to receive certain payments in connection with potential future net sales of lanifibranor, if any, which may reduce our ability to realize potential future revenue from such sales.Q4, 2023

Inventiva Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:6IVA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IOVAIOVA51Neutral$3.59B-14.64-29.71%―51.31%56.78%
KURAKURA48Neutral$713.90M-2.35-336.24%―-23.76%-33.09%
MRVIMRVI48Neutral$1.96B-16.92-31.86%―10.77%46.91%
URGNURGN43Neutral$1.28B-19.8353.97%―159.29%61.62%
MBXMBX34Underperform$2.78B-18.28-34.35%――-27.83%

* Healthcare Sector Average

Performance Comparison

0%200%400%DE:6IVAIOVAKURAURGNMRVIMBXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:6IVA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:6IVAInventiva SA ADR3.460.041.17%
IOVAIovance Biotherapeutics7.765.34220.66%
KURAKura Oncology7.77-3.08-28.39%
URGNUrogen Pharma26.182.4810.46%
MRVIMaravai Lifesciences Holdings, Inc.7.544.20125.75%
MBXMBX Biosciences, Inc.55.9430.33118.43%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.